Intelligent Radiopharmaceutical Composition Systems

The present invention relates to a novel system that integrates machine learning, IoT, blockchain, and advanced materials to create personalized, stable, and trackable radiopharmaceutical compositions for diagnostic purposes.

The original patent provided a stable radiopharmaceutical composition of tetrofosmin or its pharmaceutically acceptable salts. However, the composition's stability and efficacy were limited by the lack of personalization, inefficient manufacturing processes, and inadequate tracking mechanisms. The present invention addresses these limitations by introducing a synergistic combination of technologies to create a more powerful system.

The system consists of a machine learning model that selects the optimal tetrofosmin salt and concentration based on patient characteristics and efficacy data. The composition is then manufactured using a nanoparticle-based delivery system for targeted delivery to specific tissues or organs. The stability of the composition is monitored using IoT-enabled sensors, and the data is transmitted to a cloud-based analytics platform for analysis and prediction. The composition's provenance and authenticity are tracked using a blockchain-based platform, ensuring the integrity of the supply chain. The system also optimizes the lyophilization process using computer simulation models and real-time feedback from sensors and quality control metrics.

The new claims introduce a synergistic combination of machine learning, IoT, blockchain, and advanced materials, which is not obvious from the original patent. The integration of these technologies provides a novel and non-obvious solution to the limitations of the original patent.

Alternative embodiments of the system could include the use of different machine learning algorithms, various types of IoT sensors, or alternative blockchain platforms. The system could also be adapted for use with different radiopharmaceutical compositions or in different therapeutic areas.

The intelligent radiopharmaceutical composition system has significant commercial potential in the diagnostic imaging market, particularly in the areas of oncology, cardiology, and neurology. The system's ability to provide personalized, stable, and trackable compositions could improve patient outcomes, reduce costs, and enhance the efficiency of healthcare systems.